Drug safety in patients with heart failure [1]

Archives of Internal Medicine

Volumn 165, Issue 1, 2005, Pages 118-

  Juurlink, David N ^a   Hansten, Philip D ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE;

DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; HEART DISEASE; HEART FAILURE; HUMAN; HYPERKALEMIA; LETTER; MORBIDITY; PRIORITY JOURNAL; RISK FACTOR;

EID: 11844261411     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.1.118-a     Document Type: Letter

References (8)

1. Amabile CM, Spencer AP. Keeping your patient with heart failure safe: a review of potentially dangerous medications. Arch Intern Med. 2004;164:709-720.
2. Pitt B, Zannad F, Remme WJ, et al; the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
3. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211-214.
4. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110:438-441.
5. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ. 2003;327:1141-1142.
6. Vanpee D, Swine CH. Elderly heart failure patients with drug-induced serious hyperkalemia. Aging (Milano). 2000;12:315-319.
7. Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ. 2003;327:147-149.
8. Berry C, McMurray JJ. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart. 2001;85:E8.